VTYX Ventyx Biosciences
- 3.930
- -0.130-3.20%
- 3.940
- +0.010+0.25%
Ventyx Biosciences News
Ventyx Biosciences (VTYX) Gets a Buy From LifeSci Capital
Ventyx Biosciences Analyst Ratings
Buy Rating Affirmed for Ventyx Biosciences on Strong Clinical Pipeline and Promising Drug Developments
Buy Rating Affirmed: Ventyx Biosciences' Promising Clinical Advances and Strategic Position for Market Opportunities
Ventyx Biosciences (VTYX) Receives a New Rating From Piper Sandler
Oppenheimer Upgrades Ventyx Biosciences to Outperform, Announces $12 Price Target
Maintaining Hold on Ventyx Biosciences Amidst Anticipation of NLRP3 Inhibitor Data and Financial Stability
Lifesci Capital Upgrades Ventyx Biosciences to Outperform From Market Perform, $5 Price Target
Ventyx Biosciences (VTYX) Receives a Buy From Piper Sandler
Analysts Have Conflicting Sentiments on These Healthcare Companies: Irhythm Technologies (IRTC), Ventyx Biosciences (VTYX) and Rewalk Robotics (LFWD)
Hold Rating on Ventyx Biosciences Amid Promising but Early-Stage NLRP3 Inhibitor Development
Maintaining Hold on Ventyx Biosciences Amidst Anticipation of Clinical Catalysts and Preclinical Success
Wells Fargo Maintains Equal-Weight on Ventyx Biosciences, Lowers Price Target to $3
Ventyx Biosciences Analyst Ratings
Ventyx Biosciences Cuts 20% of Workforce
Ventyx Biosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Oncternal Therapeutics (ONCT) and Ventyx Biosciences (VTYX)
Maintaining Buy Rating for Ventyx Biosciences Despite Program Halt: A Look at the Potential of Crohn's Disease and Ulcerative Colitis Trials
Oppenheimer Downgrades Ventyx to Perform, Removes Price Target
Ventyx Biosciences Analyst Ratings
Analysis
Price Target
No Data
